Coca-Cola shares, Johnson & Johnson shares & Co.: Investors on the NYSE should keep an eye on these dividend stocks

The NYSE offers investors a variety of opportunities to invest in proven dividend stocks. The following stocks have established themselves as reliable dividend payers and are thus attracting the attention of market participants.

• Attractive investment opportunities in dividend stocks
• Growing dividends, some for decades
• Coca-Cola shares, Johnson & Johnson stocks & Co. at a glance

Dividend stocks play an important role for many investors. Regular distributions of profits to shareholders represent an attractive way to generate long-term returns. The Motley Fool recommends focusing on the following NYSE stocks in particular this year.

AbbVie stock

AbbVie is a biotechnology and pharmaceutical company that was formed in 2013 as a spin-off from Abbott Laboratories. Since then, AbbVie has been able to increase its dividend by 285 percent. The current payout is $6.20 per share, which corresponds to a yield of approximately 3.08 percent. Dividend growth remains a high priority for the North Chicago company, as AbbVie itself emphasized in its most recent earnings release.

The competition between Humira, the drug with the highest sales to date, and biosimilars is resulting in falling sales, according to The Motley Fool. As a result, two newer immunology drugs, Rinvoq and Skyrizi, are now expected to exceed Humira’s previous sales by the end of the decade. In addition, AbbVie also benefits from a comprehensive portfolio of other important medications.

“All of this means the stock could deliver incremental growth – and dividends – as AbbVie moves closer to its goals,” writes The Motley Fool. So far this year, the share on the NYSE has increased by 5.77 percent to most recently 164.92 US dollars (as of: closing price on January 30, 2024).

Coca-Cola: dividends for over 100 years

Coca-Cola describes itself as the largest beverage company in the world. Headquartered in Atlanta, the group sells over 5,000 different products under more than 500 different brands in more than 200 countries worldwide. Since the demand for drinks is basically always there, Coca-Cola generates a stable cash flow. The company has been paying a dividend for more than 100 years – there has been consistent dividend growth since 1963. With a recent dividend of $1.84 per share, the yield was 3.06 percent. Coca-Cola benefits from the strength of its brand and pays out around 76 percent of its free cash flow as dividends.

Last year, the group was able to further increase its profits – despite inflation. “So you can expect Coca-Cola to gradually increase its earnings and dividends almost regardless of the economic environment, making it a top stock to buy and hold for the long term,” writes The Motley Fool. On the NYSE, Coca-Cola shares have increased by around 1.36 percent since the beginning of the year to most recently reach $59.73 (as of January 30, 2024).

Johnson & Johnson has paid dividends for 58 years

Johnson & Johnson is a leading healthcare company. It has been continuously increasing its payouts for 58 years because it is important for the company to pay a dividend. This is currently $4.76 per share, which corresponds to a yield of 2.95 percent.

Last year, Johnson & Johnson spun off its slower-growing consumer health business to focus more on its higher-growth pharmaceutical and medical device businesses.

The global pharmaceutical and consumer goods manufacturer headquartered in New Brunswick, New Jersey, continues to plan further growth: 20 new medications and 50 expansions of existing products are to be brought onto the market by 2030.

The J&J share has increased its value on the NYSE so far this year by around 1.67 percent to most recently 159.36 US dollars (as of the closing price on January 30, 2024).

For investors who rely on dividend stocks, these NYSE stocks could be worth a look.

Editorial team finanzen.net

This text is for informational purposes only and does not constitute an investment recommendation. finanzen.net GmbH excludes any claims for recourse.

Selected leverage products at Abbott Laboratories

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products at Abbott Laboratories

Advertising

ttn-28